Classement en actions
#31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Prix de l'action
$0.04443294
Dernière synchronisation: 2026-09-24
Capitalisation boursière
$13.65M
Changement (1 jour)
0.00%
Changement (1 an)
-35.28%
Échange Noxopharm Limited (NOX)
Bénéfices pour Noxopharm Limited (NOX)
Bénéfices en Jun 2026 TTM : $-4.15M
Selon les derniers rapports financiers de Noxopharm Limited, les bénéfices actuels de l'entreprise sont de $-4.15M. En 2024, l'entreprise a réalisé un bénéfice de $-3.99M, une augmentation par rapport à celui de 2023 qui était de $-14.02M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Noxopharm Limited de 2016 à 2026
Bénéfices à la fin de chaque année
| Année |
Bénéfices |
Changez |
|
2026 (TTM) |
$-4.15M |
29.05%
|
|
2025 |
$-3.22M |
-19.45%
|
|
2024 |
$-3.99M |
-71.53%
|
|
2023 |
$-14.02M |
-15.43%
|
|
2022 |
$-16.58M |
136.55%
|
|
2021 |
$-7.01M |
23.32%
|
|
2020 |
$-5.68M |
-50.43%
|
|
2019 |
$-11.46M |
-19.51%
|
|
2018 |
$-14.24M |
507.24%
|
|
2017 |
$-2.35M |
334.19%
|
|
2016 |
$-540.21K |
0.00%
|
Bénéfices des entreprises similaires ou concurrentes
| Entreprise |
Bénéfices |
Différence de bénéfices |
Pays |
|
|
$5.27B |
-127,225.42%
|
US
|
|
|
$-3.09B |
74,296.89%
|
US
|
|
|
$-4.02B |
96,690.59%
|
AU
|
|
|
$1.95B |
-47,110.79%
|
NL
|
|
|
- |
-
|
CH
|
